Latest Articles
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia - Business Wire
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Business Wire
Published: Dec. 2, 2025, 1:05 p.m.
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia - Stock Titan
Bayer (BAYRY) starts SUNFLOWER Phase III Mirena trial for nonatypical endometrial hyperplasia Stock Titan
Published: Dec. 2, 2025, 1:05 p.m.
Singapore start-up raises US$1.5m to redefine menstrual health - FemTech World
Singapore start-up raises US$1.5m to redefine menstrual health FemTech World
Published: Dec. 2, 2025, 12:49 p.m.
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts phase III study with Mirena for treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia - MarketScreener
Bayer starts new phase III study with Mirena for the treatment of nonatypical endometrial hyperplasia MarketScreener
Published: Dec. 2, 2025, 7:36 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer
Published: Dec. 2, 2025, 7:30 a.m.
Pain, emotional distress, and fear of recurrence or progression in people with endometriosis: a network approach.
Pain is a common debilitating symptom reported in people with endometriosis. Yet, we do not have a good understanding of factors that may contribute to higher pain and worse psychosocial …
Published: Dec. 2, 2025, midnight
The pelvic pain bias assessment: a new assessment of interpretation bias specific to pelvic pain.
Pelvic pain is a common and often debilitating experience with limited treatment options. Improving understanding of the psychosocial mechanisms involved in pelvic pain experiences will enhance the efficacy of pain …
Published: Dec. 2, 2025, midnight
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials - BiotechDispatch
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials BiotechDispatch
Published: Dec. 1, 2025, 11:34 p.m.
Get Peacock Premium for free with Instacart+ - Mashable
Get Peacock Premium for free with Instacart+ Mashable
Published: Dec. 1, 2025, 6:02 a.m.
Link copied to clipboard!